CloudMD to Acquire iMD Health Global Corp., a Revolutionary Patient Engagement Software Company

• Award-winning patient engagement software providing peer- reviewed, educational resources for patients about their conditions and treatment plans
  
• Access to 7.5 million patients, with over 10,000 healthcare professionals and other users, and 60 healthcare associations globally already using iMD
• Featuring over 80,000 content resources (images, brochures and videos), covering 2,100 health conditions, including content licensed from the world-renowned Mayo Clinic library
• Content partnerships with pharmaceuticals companies including, Astra Zeneca, Novartis, Sanofi,  Bayer, Johnson&Johnson, etc.
• Synergistic across all verticals of CloudMD’s business and shared vision of holistic, engaged patient centric care
• Aggressive global growth plans with significant upside potential and projected YoY revenue increases

VANCOUVER, British Columbia, Sept. 14, 2020 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telehealth company revolutionizing the delivery of healthcare to patients, is pleased to announce that it has entered into a Binding Term Sheet (“Term Sheet”) to acquire 100% of iMD Health Global Corp. (“iMD”), a novel, award winning platform designed for healthcare professionals at every level of care to better engage, inform and educate patients about their conditions and treatment plans. The platform features trusted, peer-reviewed healthcare resources.

iMD is a trusted platform used by healthcare professionals (including doctors, nurses, pharmacists and allied health professionals), to provide factual, medical information that promotes positive patient behaviour in all health sectors. iMD’s intuitive platform provides a robust digital library and consultative visual component which is available on any digital device. iMD’s platform is populated with content licensing partnerships with Canada’s most respected health associations, pharmaceutical companies in addition to being backed and partnered with Apotex Pharmaceuticals, one of Canada’s largest pharmaceuticals companies with $2 billion in annual sales, which currently has an 18% equity stake in iMD.